Comparison of responsiveness to cancer development and anti-cancer drug in three different C57BL/6N stocks

다국어 초록 (Multilingual Abstract)

In our efforts to understand the systemic features of tumors, the importance of animal models is increasing due to the recent growth in the development of immunotherapy and targeted therapies. This has resulted in increased attention towards tumor animal models using C57BL/6N, which are mainly used in immunological studies. In this study, the C57BL/6NKorl stock and two other commercial stocks (C57BL/6NA and C57BL/N6B) are evaluated by comparing the occurrence of tumors using the syngeneic model; furthermore, we compare the response to anti-cancer drugs in the syngeneic model by evaluating survival, growth of tumors, proliferation and molecular biology analysis. In the syngeneic model using LLC (Lewis lung carcinoma) cells, the survival of mice and growth of the tumor showed a better response in the C57BL/6NKorl stock, and was dependent on the cell concentration of the dosing tumor, as compared to the other C57BL/6N stocks. However, the Ki-67 staining showed only little difference in cell proliferation within the tumor tissue each mouse stocks. Comparing the sensitivity to anti-cancer drug by examining changes in growth, volume and weight revealed that cisplatin treatment for tumor-bearing C57BL/6NKorl was more dependent on concentration. The Ki-67 staining, however, showed no difference among the C57BL/6N stocks after cisplatin treatment. The expressions of p27 and p53 tumor suppressor proteins, caspase-3 and Bax showed dose-dependent increase after exposure to cisplatin, whereas the expression of Bcl-2 was reduced in a dose-dependent manner. Furthermore, the expressions of MMP-2 and VEGF involved in metastasis, as well as inflammatory genes IL-1β, IL-6 and IL-10, showed dose-dependent decrease in tumor tissue after cisplatin exposure. Differences observed among the C57BL/6N stocks were not significant. Taken together, our studies reveal that C57BL/6NKorl has the potential of being a useful biological resource established in Korea, as it does not differ from the two commercially available C57BL/6N stocks when considering response to tumor generation and sensitivity to anti-cancer drugs using the syngeneic tumor model.

참고문헌 (Reference)

1 Kigawa J, "p53 gene status and chemosensitivity in ovarian cancer" 3 : 165-171, 2001

2 Efeyan A, "p53 : guardian of the genome and policeman of the oncogenes" 9 : 1006-1010, 2007

3 Yen J, "Zebrafish models of cancer : progress and future challenges" 24 : 38-45, 2014

4 Liu S, "Zebrafish models for cancer" 6 : 71-39, 2011

5 Sherman SE, "X-ray structure of the major adduct of the anticancer drug cisplatin with DNA : cis-[Pt(NH3)2{d(pGpG)}]" 230 : 412-417, 1985

6 Kondo S, "WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis" 6 : 1279-1285, 1996

7 Hall MD, "The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy" 48 : 495-53523, 2008

8 Kelland L, "The resurgence of platinum-based cancer chemotherapy" 8 : 573-584, 2007

9 Sadna B, "The importance of animal models in tumor immunity and immunotherapy" 24 : 46-51, 2014

10 Chu IM, "The Cdk inhibitor p27 in human cancer : prognostic potential and relevance to anticancer therapy" 8 (8): 253-267, 2008

11 Talmadge JE, "Role of natural killer cells in tumor growth and metastasis : C57BL/6 normal and beige mice" 65 (65): 929-935, 1980

12 Kartalou M, "Recognition of cisplatin adducts by cellular proteins" 1–2 : 1-21, 2001

13 Chen J, "Quantitative trait loci regulating relative lymphocyte proportions in mouse peripheral blood" 99 (99): 561-566, 2002

14 McKay BC, "P53 plays a protective role against UVand cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts" 46 : 6805-6808, 2001

15 Lunardi A, "Of model pets and cancer models : an introduction to mouse models of cancer" 2014 (2014): 17-31, 2014

16 Krarup-Hansen A, "Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies" 130 (130): 1076-1088, 2007

17 Bock BC, "Mouse models of human cancer" 74 : 1-5, 2014

18 Mills CD, "M-1/M-2 macrophages and the Th1/Th2 paradigm" 164 (164): 6166-6173, 2000

19 Todd RC, "Inhibition of transcription by platinum antitumor compounds" 4 : 280-291, 2009

20 Song K, "In vivo studies of adenovirus-mediated p53gene therapy for cis-platinum-resistant human ovarian tumor xenografts" 3 : 153-159, 1999

21 Glineur S, "Immune depression of the SJL/J mouse, a radioresistant and immunologically atypical inbred strain" 216 : 213-217, 2011

22 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries" 68 (68): 394-424, 2018

23 DuPage M, "Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response" 25 (25): 192-199, 2013

24 이광식, "Economic Burden of Cancer in Korea during 2000-2010" 대한암학회 47 (47): 387-398, 2015

25 Yee NS, "Drug discovery in pancreatic Cancer" Springer 95-112, 2010

26 Boehm T, "Design principles of adaptive immune systems" 11 (11): 307-317, 2011

27 Zorbas H, "Cisplatin damage : are DNA repair proteins saviors or traitors to the cell?" 7 : 1157-1166, 2005

28 Landskron G, "Chronic inflammation and cytokines in the tumor microenvironment" 2014 : 1491852014-, 2014

29 Dong W, "Cellular processing of platinum anticancer drugs" 4 : 307-320, 2005

30 Horowitz J, "Adenovirus-mediated p53 gene therapy : overview of preclinical studies and potential clinical applications" 4 : 500-509, 1999

31 McVicar DW, "Aberrant DAP12 signaling in the 129 strain of mice : implications for the analysis of gene-targeted mice" 169 (169): 1721-1728, 2002

32 Pabla N, "ATR-Chk2 signaling in p53activation and DNA damage response during cisplatin-induced apoptosis" 10 : 6572-6583, 2008

33 Chen J, "A reduced peripheral blood CD4(+) lymphocyte proportion is a consistent ageing phenotype" 123 (123): 145-153, 2002